NCBiotech News

United Therapeutics, a public benefit corporation with co-headquarters in Research Triangle Park, is poised to expand the use of its drug Tyvaso for treating a serious lung disease following positive clinical trial results.

North Carolina’s reputation as a leading state for life sciences is well-known, both in the United States and globally.

But there’s no guarantee that will always be the case. Pharmaceutical and biotechnology leaders, working in conjunction with others who are a part of the state’s life sciences ecosystem, can’t sit still while the rest of the world catches up, speakers at a recent conference in Raleigh emphasized.

The tenth edition of Triad BioNight, a celebration of bioscience growth and recognition of industry leaders in North Carolina’s Piedmont Triad region, is expected to attract over 400 attendees in May.

This long-standing, iconic event, hosted by the North Carolina Biotechnology Center and its Piedmont Triad Regional Advisory Committee, is scheduled for Wednesday, May 27, from 6:00 to 9:00 p.m., at the Grandover Resort in Greensboro.

Coriolis Pharma, a global contract research and development organization, celebrated the grand opening of its new North America headquarters and laboratory, marking the start of operations at the Alexandria Center for Advanced Technologies (ACAT) in North Carolina’s Research Triangle Park (RTP). 

With roughly 35,000 people employed in life sciences manufacturing, North Carolina has emerged as one of the leading destinations for biopharma companies building or expanding their operations. It’s no surprise, then, that the state’s biopharma manufacturers are investing heavily in technology, partnerships and people to maintain their competitive edge.

As North Carolina’s life sciences sector continues to grow, women are playing a central role in shaping its future. Across startups, pharmaceutical companies and economic development organizations, women launch companies, lead the manufacturing of new medicines and attract new companies to North Carolina — shaping North Carolina’s life sciences ecosystem at every level.

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced a $130 million Series A round of financing to advance its novel therapy.

Durham-based BioCryst Pharmaceuticals Inc. is advancing care for children living with hereditary angioedema (HAE) as it begins a new chapter under a new CEO. The company recently received approval from the U.S. Food and Drug Administration for an oral pellet formulation of ORLADEYO to help prevent HAE attacks in children ages 2 to under 12.

Health innovation in Charlotte is entering a new chapter. Anchored by The Pearl innovation district and the newly opened Charlotte campus of Wake Forest University School of Medicine, new initiatives are helping position the Queen City as a growing hub moving new ideas forward.

Fresh off a new funding round, Durham startup Ten63 Therapeutics is looking to advance its technology platform that uses artificial intelligence to unlock discoveries for difficult-to-treat cancers.

Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare muscle-degeneration disease that mostly affects boys.

Durham-based Priovant Therapeutics has announced positive results from its Phase 2 BEACON study evaluating brepocitinib in cutaneous sarcoidosis (CS). 

A trusted leader who offered a steady hand and strong leadership on an interim basis in an ever-changing research environment, Sharon Paynter, Ph.D., has been named Senior Vice Provost for Research and Innovation by the provost effective immediately, and in that role will serve as chief research officer for the university.

If 2025 had a theme for the Charlotte region's life sciences ecosystem, it was this: years of planning finally meeting their moment. From landmark facility openings to record-breaking workforce milestones, the Charlotte region didn't just grow — it announced itself to the world.

A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body. These cells, called chimeric antigen receptor T cells or “CAR-T cells,” are currently administered as a personalized immunotherapy for certain blood cancers but require time-intensive and costly manufacturing.